Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.

Amy S PallerAndreas WollenbergElaine SiegfriedDiamant ThaçiMichael J CorkPeter D ArkwrightMelinda GooderhamXian SunJohn T O'MalleyFaisal A KhokharJignesh VakilAshish BansalKarli RosnerBrad ShumelNoah A Levit

Published in: Paediatric drugs (2021)

ClinicalTrials.gov Identifier: NCT03345914. Does treatment with dupilumab require routine laboratory monitoring in 6- to 11-year-old children with severe atopic dermatitis? (MP4 180482 kb).

Keyphrases

atopic dermatitis
phase iii
clinical trial
open label
end stage renal disease
phase ii
ejection fraction
early onset
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
clinical practice
patient reported outcomes